Age‐ and gender‐specific molecular characteristics of diffuse large B‐cell lymphoma: Results from clinical trials of the DSHNHL/GLA

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Despite a high cure rate, too many patients show refractory (ref) or relapsed (rel) disease. This study examines the frequency of recurring gene mutations and their interplay with well-known biomarkers in female and male patients between 18 and 80 years with ref/rel DLBCL compared to patients with complete remission (CR) to identify biological risk factors associated with treatment response, using cohorts of R-CHOP-like treated DLBCL enrolled in clinical trials of the DSHNHL. The biomarker profile of patients differed between younger and elderly patients with ref/rel DLBCL, with a higher frequency of <i>BCL2</i> translocations in younger patients, and higher numbers of ABC subtypes and MYC protein expression in the elderly. Amplicon sequencing revealed generally higher mutation frequencies in the younger cohort. Mutations in <i>CREBBP</i> and <i>TNFRSF14</i> were associated with shorter overall survival (OS) only in younger patients. A higher proportion of <i>GNA13</i> mutations was detected in female patients of the elderly DLBCL patient cohort, clearly emphasizing the striking differences in biomarker distribution between younger and elderly as well as female and male patients.

Authors

Institutions

Publication Details

Journal
HemaSphere
Published
2025-03-01
DOI
https://doi.org/10.1002/hem3.70093
Citations
1
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
1.47

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Age‐ and gender‐specific molecular characteristics of diffuse large B‐cell lymphoma: Results from clinical trials of the DSHNHL/GLA

Katrin S. Kurz, Norbert Schmitz, Markus Kreuz, Sylvia Hartmann et al.
1 citations
HemaSphere
Lymphoma Diagnosis and Treatment
1.47
article

Age‐ and gender‐specific molecular characteristics of diffuse large B‐cell lymphoma: Results from clinical trials of the DSHNHL/GLA

Katrin S. Kurz, Norbert Schmitz, Markus Kreuz, Sylvia Hartmann, Markus Loeffler, Andreas Rosenwald, Annette M. Staiger, Sophia Steinlein, Marita Ziepert, German Ott, Harald Stein, Alfred C. Feller, Thomas F.E. Barth, Julia Richter, Wolfram Klapper, Peter Mӧller, Martin‐Leo Hansmann, Heinz‐Wolfram Bernd, Lorenz Trümper, Heike Horn
article en
1 citations

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Despite a high cure rate, too many patients show refractory (ref) or relapsed (rel) disease. This study examines the frequency of recurring gene mutations and their interplay with well-known biomarkers in female and male patients between 18 and 80 years with ref/rel DLBCL compared to patients with complete remission (CR) to identify biological risk factors associated with treatment response, using cohorts of R-CHOP-like treated DLBCL enrolled in clinical trials of the DSHNHL. The biomarker profile of patients differed between younger and elderly patients with ref/rel DLBCL, with a higher frequency of <i>BCL2</i> translocations in younger patients, and higher numbers of ABC subtypes and MYC protein expression in the elderly. Amplicon sequencing revealed generally higher mutation frequencies in the younger cohort. Mutations in <i>CREBBP</i> and <i>TNFRSF14</i> were associated with shorter overall survival (OS) only in younger patients. A higher proportion of <i>GNA13</i> mutations was detected in female patients of the elderly DLBCL patient cohort, clearly emphasizing the striking differences in biomarker distribution between younger and elderly as well as female and male patients.

HemaSphereVol. 9(3)
Goethe University Frankfurt (DE), University of Würzburg (DE), Robert Bosch Hospital (DE), University Hospital Münster (DE), University Hospital Schleswig-Holstein (DE), Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (DE), University Hospital Frankfurt (DE), Pathodiagnostik Berlin (DE), Fraunhofer Institute for Cell Therapy and Immunology (DE), University Hospital Ulm (DE), University of Göttingen (DE), University of Tübingen (DE), Leipzig University (DE), University of Lübeck (DE)
Robert Bosch Stiftung
Good health and well-being
Openalex Percentile: Top 22%
Lymphoma Diagnosis and Treatment
1.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.